OLMA

Rating neutralAI Memo

Olema

As of 2026-08-04/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-04 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

OPERA-01 Phase 3 top-line data • 2026-11-02

Base target: $11 / p=50% prob

Biggest risk

The thesis remains concentrated in palazestrant and exposed to binary Phase 3 outcomes. The company reported a $53.1 million quarterly net loss and $49.2 million of R&D expense, while the packet provides no confirmed post-readout analyst revisions or market-reaction evidence.

Invalidation

Break below $8 or thesis failure.

What would change my mind?

Successful OPERA-01 data could materially re-rate OLMA, with OPERA-02, OP-3136, and partnered studies providing additional pipeline optionality. The reported cash position reduces immediate financing pressure.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-04

Base target

$11

p=50%

Bull target

$18

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Director open-market sales add near-term overhang
Pipeline advancement and financing runway
Successful OPERA-01 data could materially re-rate OLMA, with OPERA-02, OP-3136, and partnered studies providing additional pipeline optionality.

BearKey bullets

OPERA-01 Phase 3 results could disappoint or be delayed.
OPERA-02 enrollment and OP-3136 development may require continued high spending without near-term revenue.
Quarterly losses and R&D intensity create ongoing cash-burn and potential financing risk despite the reported cash balance.

WatchKey bullets

OPERA-01 Phase 3 top-line data

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $11 (p=50%)

Target spread vs base: +67% / -31%

Scenario probabilities

Bull Target: $18 (p=20%)Base Target: $11 (p=50%)Bear Target: $8 (p=30%)

Commentary

Cautious monitoring view. Primary company and SEC materials support a clear fall 2026 clinical catalyst and substantial reported cash, but the thesis remains binary, coverage is low, and verified analyst-revision or post-print market-reaction data are unavailable. Social sentiment is not available in the packet; the only recent headline is low-signal secondary coverage.

As of 2026-08-04 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Director open-market sales add near-term overhang
Pipeline advancement and financing runway

Scenarios

Bull Target (Scenario probability)

$18 / p=20% prob

Base Target (Scenario probability)

$11 / p=50% prob

Bear Target (Scenario probability)

$8 / p=30% prob

Analysis 2026-08-04 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-02
OPERA-01 Phase 3 top-line data
Olema's latest earnings update anticipated top-line data from the pivotal Phase 3 OPERA-01 monotherapy trial in fall 2026. The readout is the primary near-term value driver and remains binary [#SEC-8K-2026-05-12][#PR-EARNINGS-2026-05-12].
Prob 60.00% • Move 40.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

Director open-market sales add near-term overhang
2026-08-31
Director Cyrus Harmon reported two open-market sales totaling 25,000 shares on July 23-24 at $11.579-$11.714 per share. This is a sentiment and supply risk, not evidence of operating deterioration [#SEC-FORM4-2026-07-27].
Prob 55% • Move -5% • Priced-in 60%

Long-term Catalysts

Months to a year

Pipeline advancement and financing runway
2026-12-31
The company reported $505.3 million in cash, cash equivalents, and marketable securities at March 31, 2026, while continuing OPERA-02 enrollment and advancing OP-3136 and partnered combination studies. This supports execution through upcoming clinical milestones, though ongoing losses and R&D spending remain material [#SEC-8K-2026-05-12].
Prob 70% • Move 10% • Priced-in 65%

Risks

OPERA-01 Phase 3 results could disappoint or be delayed.
OPERA-02 enrollment and OP-3136 development may require continued high spending without near-term revenue.
Quarterly losses and R&D intensity create ongoing cash-burn and potential financing risk despite the reported cash balance.
Recent director open-market sales may add short-term sentiment pressure [#SEC-FORM4-2026-07-27].
The packet lacks verified analyst estimate revisions, target changes, and post-earnings market-reaction attribution.

Peers

Symbol	Summary
ARVN	Closest public comparator through a competing ER-targeting breast-cancer program; direct comparison is limited by differing clinical data and development timing.
AZN	Relevant larger breast-cancer and endocrine-therapy comparator, but broad and not a clean market-cap or pipeline peer.
LLY	Relevant through ER-positive breast-cancer exposure, but its scale and commercial portfolio make it an adjacent rather than direct valuation peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-04

Loading AI feed…

Symbol

Summary

ARVN

Closest public comparator through a competing ER-targeting breast-cancer program; direct comparison is limited by differing clinical data and development timing.

AZN

Relevant larger breast-cancer and endocrine-therapy comparator, but broad and not a clean market-cap or pipeline peer.

LLY

Relevant through ER-positive breast-cancer exposure, but its scale and commercial portfolio make it an adjacent rather than direct valuation peer.